US2003022291A1PendingUtilityA1

Production of a multimeric protein by cell fusion method

Priority: Oct 11, 1996Filed: May 24, 2002Published: Jan 30, 2003
Est. expiryOct 11, 2016(expired)· nominal 20-yr term from priority
C07K 14/00C12N 5/16C12N 15/62C12N 5/166C07K 2317/21C07K 16/244C12N 2510/02C07K 16/00
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention features a method of producing a multimeric protein from a hybrid cell formed from the fusion of two or more cells, each of which cell is engineered to express one component of the multimeric protein, as well as a method for screening for successful fusion of the cells to produce a desired hybrid cell. The methods of the invention are widely applicable to the production of proteins having two or more components.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for producing a multi-component protein, said method comprising: 
 (a) introducing a first nucleotide sequence into a first cell, wherein the first nucleotide sequence encodes a first component of the multi-component protein;    (b) introducing a second nucleotide sequence into a second cell, wherein the second nucleotide sequence encodes a second component of the multi-component protein;    (c) optionally, repeating step (b) for each remaining component of the multi-component protein; and    (d) fusing cells produced from steps (a)-(c) to form a hybrid cell, wherein the hybrid cell expresses the multi-component protein.    
     
     
         2 . The method of  claim 1 , further comprising: 
 (e) culturing the hybrid cells so as to express the multi-component protein; and    (f) recovering the multi-component protein from the hybrid cell culture.    
     
     
         3 . The method of  claim 1 , wherein said first cells and said second cells are selected from the group consisting of a mammalian cell, a myeloma cell, and a non-lymphoid cell.  
     
     
         4 . The multi-component protein of  claim 1 , wherein said protein is an antibody.  
     
     
         5 . A method for producing an antibody, said method comprising: 
 (a) introducing a nucleotide sequence encoding a desired heavy chain into a first cell;    (b) introducing a nucleotide sequence encoding a desired light chain into a second cell; and    (c) fusing the first and second cells to form a hybrid cell, wherein the hybrid cell expresses the antibody.    
     
     
         6 . The method of  claim 5 , further comprising: 
 (e) culturing the hybrid cells so as to express the multi-component protein; and    (f) recovering the multi-component protein from the hybrid cell culture.    
     
     
         7 . The method of  claim 5 , wherein said nucleotide sequence is obtained from a B-cell or a hybridoma cell, wherein said B-cell or hybridoma cell produce an antibody.  
     
     
         8 . The method of  claim 5 , wherein the first cell expresses an irrelevant light chain and expresses the desired heavy chain prior to fusion with the second cell.  
     
     
         9 . The method of  claim 5 , wherein expression of the desired heavy chain by the first cell is determined by ELISA analysis of lysate from the first cell.  
     
     
         10 . The method of  claim 5 , wherein the antibody is expressed only after fusion of said first and second cells.  
     
     
         11 . The method of  claim 5 , wherein the first cell expressing the desired heavy chain is further selected for one or more desirable characteristics.  
     
     
         12 . The method of  claim 5 , wherein both the second cell expressing the desired light chain and the first cell expressing the desired heavy chain are each further selected for one or more desirable characteristics.  
     
     
         13 . The method of  claim 12 , wherein said desirable characteristic is selected from the group consisting of high production rate of the heavy chain and high production rate of light chain.  
     
     
         14 . A method for producing an antibody, said method comprising: 
 (a) introducing a nucleotide sequence encoding a desired heavy chain into a first cell, wherein the first cell expresses an irrelevant light chain;    (b) introducing a nucleotide sequence encoding a desired light chain into a second cell; and    (c) fusing the first and second cells to form a hybrid cell, wherein the hybrid cell expresses the antibody.    
     
     
         15 . The method of  claim 14 , further comprising: 
 (e) culturing the hybrid cells so as to express the multi-component protein; and    (f) recovering the multi-component protein from the hybrid cell culture.    
     
     
         16 . The method of  claim 14 , wherein said irrelevant light chain is present in an episomal vector.  
     
     
         17 . A multi-component protein produced by the method of  claim 1 .  
     
     
         18 . An antibody produced by the method of  claim 5 .  
     
     
         19 . A antibody produced by the method of  claim 14 .  
     
     
         20 . A method for screening for successful fusion of a first cell containing a first nucleotide sequence encoding a desired antibody heavy chain and a second cell containing a second nucleotide sequence encoding a desired antibody light chain, comprising: 
 including a nucleotide sequence encoding a first marker gene in the first cell;    including a nucleotide sequence encoding a second marker gene in the second cell;    fusing the first cell and the second cell under fuseogenic conditions to produce a fused cell; and    assaying for the presence of the first and second marker genes in the fused cell, wherein detection of the presence of the first and second marker genes in the fused cell indicates a successful fusion.    
     
     
         21 . The method of  claim 20 , wherein the first marker gene is independently selected from the group consisting of the hygromycin resistance gene, the neomycin resistance gene, the hypoxanthine phosphoribosyl transferase gene, the dihydrofolate reductase gene, and the LacZ reporter gene and the second marker gene is independently selected from the group consisting of the hygromycin resistance gene, the neomycin resistance gene, the hypoxanthine phosphoribosyl transferase gene, the dihydrofolate reductase gene, and the LacZ reporter gene.  
     
     
         22 . The method of  claim 20 , wherein the first marker gene is the hypoxanthine phosphoribosyl transferase and the second marker gene is the LacZ reporter gene.  
     
     
         23 . The method of  claim 20 , wherein the first marker gene is the LacZ reporter gene and the second marker gene is the hypoxanthine phosphoribosyl transferase gene.

Join the waitlist — get patent alerts

Track US2003022291A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.